T2DM patients have a noticeablyreduced circulating myonectin level compared with the control group.Additionally, serum myonectin levels were notably lower in the obese non-diabeticcontrol cohort than in the lean non-diabetic control group. This evidence concerns the gene ERFE and type 2 diabetes mellitus.